Does Metrnl ameliorate myocardial ischemia-reperfusion injury?
Metrnl demonstrates therapeutic potential for ischemic heart disease by ameliorating myocardial ischemia-reperfusion injury via AMPK-mediated M2 macrophage polarization.
Metrnl alleviates MI/RI by activating AMPK-mediated M2 macrophage polarization to attenuate inflammatory response and cardiomyocyte apoptosis. This study highlights the therapeutic potential of Metrnl in MI/RI, and identifies it as a promising target for the treatment of ischemic heart disease.
Chen et al. (Thu,) studied this question.